DeepMed Research

Huperzine A

Generic Name: Huperzine A

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₈N_₂O

CAS Number: 102518-79-6

Unique Ingredient Identifier: 0111871I23

Background: Huperzine A, is a naturally occurring sesquiterpene alkaloid found in the extracts of the firmoss Huperzia serrata. The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.

Indication: Investigated for use/treatment in alzheimer's disease.

Clinical Trials

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures

Phase 2

Recruiting

Conditions: Focal Onset Seizures

Interventions: Drug: SPN-817
Drug: Placebo

First Posted Date: 2025-01-29

Last Posted Date: 2025-02-06

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 258

Registration Number: NCT06798896

Locations: 🇺🇸
Medsol Clinical Research Center, Port Charlotte, Florida, United States

The Study of Ginkgo Leaf Dropping Pills and Huperzine a Injection Combined with Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury

Phase 4

Recruiting

Conditions: Cognitive Impairment After Brain Injury

Interventions: Other: Median nerve electrical stimulation treatment
Drug: Huperzine A injection
Drug: Ginkgo leaf dropping pill

First Posted Date: 2024-11-26

Last Posted Date: 2024-12-11

Lead Sponsor: Wanbangde Pharmaceutical Group Co., LTD

Target Recruit Count: 50

Registration Number: NCT06704334

Locations: 🇨🇳
The Ganzhou City People's Hospital, Ganzhou, Jiang Xi province, China

The Study of Pharmacokinetics and Pharmacodynamics of Huperzine a Injection in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Huperzine A injection

First Posted Date: 2024-08-26

Last Posted Date: 2024-12-19

Lead Sponsor: Wanbangde Pharmaceutical Group Co., LTD

Target Recruit Count: 12

Registration Number: NCT06570655

Locations: 🇨🇳
Clinical trial institution of the Zhejiang Xiaoshan hospital, Hangzhou, China/Zhejiang, China

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Phase 2

Recruiting

Conditions: Epilepsy
Seizures, Epileptic

Interventions: Drug: SPN-817

First Posted Date: 2022-08-26

Last Posted Date: 2023-03-20

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 35

Registration Number: NCT05518578

Locations: 🇦🇺
Alfred Hospital, Melbourne, Australia

A Study of Huperzine A Injection in Reducing Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Surgery

Not Applicable

Recruiting

Conditions: Injection
Non-cardiac Surgery
Delirium in Old Age
Post Operative Delirium

Interventions: Drug: Sodium Chloride Injection
Drug: Huperzine A Injection

First Posted Date: 2022-02-16

Last Posted Date: 2025-04-02

Lead Sponsor: Second Affiliated Hospital of Wenzhou Medical University

Target Recruit Count: 40

Registration Number: NCT05242419

Locations: 🇨🇳
The 2nd Second Affiliated Hospital of WMU Phase I Clinical Trial Unit /Center Of Bioequivalence Study, Wenzhou, Zhejiang, China

Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage

Phase 4

Conditions: Neurosensory Disorder

Interventions: Drug: Huperzine A for Injection

First Posted Date: 2020-08-12

Last Posted Date: 2020-08-12

Lead Sponsor: Jiangsu Famous Medical Technology Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT04509323

Locations: 🇨🇳
The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

Phase 1

Active, not recruiting

Conditions: Focal Impaired Awareness Seizures

Interventions: Drug: BIS-001ER

First Posted Date: 2018-03-23

Last Posted Date: 2022-08-30

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 16

Registration Number: NCT03474770

Locations: 🇦🇺
The Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia

Bioavailability, Safety, and Tolerability of BIS-001 ER

Phase 1

Completed

Conditions: Epilepsy, Complex Partial

Interventions: Drug: BIS-001 ER

First Posted Date: 2017-05-17

Last Posted Date: 2018-01-18

Lead Sponsor: Supernus Pharmaceuticals, Inc.

Target Recruit Count: 8

Registration Number: NCT03156439

Locations: 🇦🇺
The Royal Melbourne Hospital, Parkville, Victoria, Australia

Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging

Phase 4

Not yet recruiting

Conditions: Mild Cognitive Impairment
Biomarker
Diagnosis
Treatment

Interventions: Drug: Placebo
Drug: Huperzine A

First Posted Date: 2016-10-12

Last Posted Date: 2019-04-16

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 300

Registration Number: NCT02931136

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China

Effects of Huperzine A in Treatment of Moderate to Severe TBI

Phase 2

Terminated

Conditions: Traumatic Brain Injury

Interventions: Drug: Placebo
Drug: Huperzine A

First Posted Date: 2012-08-30

Last Posted Date: 2019-11-05

Lead Sponsor: Spaulding Rehabilitation Hospital

Target Recruit Count: 14

Registration Number: NCT01676311

Locations: 🇺🇸
Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy